RO7112689/F03-03 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
62Paroxysmal nocturnal hemoglobinuria1

62. Paroxysmal nocturnal hemoglobinuria


Clinical trials : 271 Drugs : 163 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 106
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-002128-10-DE
(EUCTR)
14/03/201724/10/2016A Study to Assess Safety, Effectiveness, Pharmacokinetics, and Pharmacodynamics of crovalimab in Healthy Volunteers and Patients With Paroxysmal Nocturnal HemoglobinuriaAn adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of crovalimab in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) Paroxysmal nocturnal hemoglobinuria (PNH)
MedDRA version: 21.1;Level: LLT;Classification code 10055629;Term: Paroxysmal nocturnal hemoglobinuria;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Code: RO7112689/F01
INN or Proposed INN: Not available
Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230
Product Code: RO7112689/F03-01
INN or Proposed INN: Not available
Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230
Product Code: RO7112689/F03-03
INN or Proposed INN: Not available
Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230
F. Hoffmann-La Roche LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
49Phase 1;Phase 2France;Hungary;Netherlands;Germany;Italy;Japan;Korea, Republic of